Surrogate Endpoint, Safety Questions May Be Too Much For Waylivra To Overcome At US FDA Panel

Akcea Therapeutics' familial chylomicronemia syndrome drug will be faced with questions about its surrogate endpoint and a thrombocytopenia safety signal.